Compare Crispr Therapeutics AG (CRSP) vs Visa Inc (V) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Visa Inc — how do they compare? Crispr Therapeutics AG trades at $53.97 (market cap $5.23B), while Visa Inc trades at $361.75 (market cap $671.74B). The key difference: Visa Inc is far larger — about 128.4× Crispr Therapeutics AG's market cap, and Visa Inc pays a 0.74% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | V | |
|---|---|---|
Market Cap | $5.23B | $671.74B |
Sector | Health | Financials |
52-Week High | $76.78 | $370.47 |
52-Week Low | $44.34 | $295.52 |
Enterprise Value | $3.65B | $682.32B |
Volume | — | 10,431,336 |
Dividend Yield | — | 0.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Visa (V) trades at $361.32, down 0.33% on the day, with a bearish technical signal but strong fundamentals including a 50.78% net income margin and consistent earnings beats. Recent news highlights AI-driven commerce initiatives and stablecoin partnerships, positioning the company for future growth. The stock is near its pivot point of $361, with support at $359 and resistance at $364.
The outlook remains positive with an 85% analyst buy rating and a $426.31 consensus price target, implying 18% upside. Risks include fintech competition and regulatory pressures, but Visa's robust cash flow and high profitability support long-term value. The next earnings report on April 28, 2026, will be a key catalyst.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Visa Inc
Visa Inc. operates a retail electronic payments network and manages global financial services. The Company also offers global commerce through the transfer of value and information among financial institutions, merchants, consumers, businesses, and government entities.
Read more on V →
